Verana Health, a digital health company that delivers quality drug lifecycle and medical practice insights from an exclusive real-world data network, announced that it has launched Qdata™ Glaucoma. Qdata Glaucoma is the first-and-only data module reflective of a full, real-world glaucoma patient journey to accelerate quality insights. The fit-for-purpose data module comprises more than 5 million de-identified patients, ranging from suspect diagnosis through treatment and outcomes.
Also Read: Wedge Partners with Sila Adding Speed and Security to Smart Debit Card
Qdata Glaucoma is powered by real-world glaucoma data from the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight), which is managed and analyzed by the Academy and Verana Health. Qdata Glaucoma enables insight generation for life sciences organizations using high-quality glaucoma data. The module also delivers the most comprehensive view of the glaucoma patient journey to enable new insights into treatment patterns and outcomes, postmarketing safety, comparative effectiveness, and label expansion and modification.
Qdata Glaucoma uniquely combines exclusive structured and unstructured electronic health record data from ophthalmologists with medical and pharmacy claims from millions of de-identified glaucoma patients treated by more than 15,000 clinicians via Verana Health’s VeraQ™ population health data engine. Verana Health then tokenizes, harmonizes, cleanses, and curates the data with artificial intelligence as well as verification and oversight from clinicians with glaucoma expertise to provide meaningful insights from glaucoma-specific outcomes and risk factors, such as elevated intraocular pressure (IOP).
“One of the unique aspects about Qdata Glaucoma is that the treatment and outcomes data are specific to a given eye,” said Robert Chang, MD, Associate Professor of Ophthalmology, Stanford University. “Verana Health has a unique team of clinicians, data scientists, and research design experts all working together to ensure accuracy as well as acknowledge some limitations in real-world big data.”